CG
ABBV icon

CFO4Life Group’s AbbVie ABBV Stock Holding History

CFO4Life Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$439K Sell
1,745
-405
-19% -$87.1K 0.06% 142
2026
Q1 		$468K Sell
2,150
-1,195
-36% -$265K 0.07% 128
2025
Q4 		$764K Sell
3,345
-33
-1% -$7.52K 0.11% 93
2025
Q3 		$782K Buy
3,378
+87
+3% +$17.7K 0.11% 91
2025
Q2 		$611K Sell
3,291
-20
-0.6% -$3.72K 0.1% 111
2025
Q1 		$694K Buy
3,311
+114
+4% +$22.2K 0.12% 89
2024
Q4 		$568K Buy
3,197
+212
+7% +$39K 0.1% 110
2024
Q3 		$589K Buy
2,985
+100
+3% +$18.7K 0.1% 109
2024
Q2 		$495K Sell
2,885
-23
-0.8% -$3.81K 0.09% 114
2024
Q1 		$530K Sell
2,908
-252
-8% -$43.4K 0.1% 111
2023
Q4 		$490K Sell
3,160
-691
-18% -$101K 0.09% 111
2023
Q3 		$574K Buy
3,851
+93
+2% +$13.7K 0.13% 92
2023
Q2 		$506K Sell
3,758
-456
-11% -$66.9K 0.11% 102
2023
Q1 		$672K Sell
4,214
-201
-5% -$30.7K 0.15% 76
2022
Q4 		$713K Buy
4,415
+483
+12% +$74.1K 0.15% 76
2022
Q3 		$528K Sell
3,932
-788
-17% -$113K 0.14% 80
2022
Q2 		$706K Buy
4,720
+161
+4% +$24.6K 0.18% 60
2022
Q1 		$739K Buy
4,559
+178
+4% +$25.9K 0.16% 66
2021
Q4 		$593K Buy
4,381
+1,564
+56% +$185K 0.12% 88
2021
Q3 		$304K Hold
2,817
– – 0.07% 110
2021
Q2 		$317K Sell
2,817
-367
-12% -$41.3K 0.07% 107
2021
Q1 		$345K Sell
3,184
-103
-3% -$11K 0.09% 112
2020
Q4 		$352K Buy
+3,287
New +$316K 0.1% 107
2020
Q1 		– Sell
-2,489
Closed -$220K – 118
2019
Q4 		$220K Buy
+2,489
New +$207K 0.09% 113

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CFO4Life Group's ABBV Position: Q2 2026 in Review

CFO4Life Group reduced its AbbVie (ABBV) stake by 19% in Q2 2026, selling an estimated $87.1K and leaving 1,745 shares worth $439K. The position accounts for 0.06% of the portfolio, ranked #142.

CFO4Life Group first reported a position in ABBV in Q4 2019 and has held it in 24 quarters since. The position peaked at $782K in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • CFO4Life Group held 1,745 shares of AbbVie worth $439K as of Q2 2026.
  • CFO4Life Group sold 405 AbbVie shares in Q2 2026, an estimated $87.1K.
  • AbbVie made up 0.06% of CFO4Life Group's portfolio in Q2 2026, its #142 holding.
  • CFO4Life Group first reported a position in AbbVie in Q4 2019 and has held it in 24 quarters since.
  • CFO4Life Group's AbbVie position peaked at $782K in Q3 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CFO4Life Group's 13F filing for Q2 2026, filed 12 Aug 2026.